Indicated for the triage and notification of obstructive hydrocephalus on non-contrast brain computed tomography (CT), the artificial intelligence (AI)-enabled software is reportedly the first radiology triage modality to obtain the Food and Drug Administration’s (FDA) Breakthrough Device Designation.
The Food and Drug Administration (FDA) has granted 510(k) clearance for a new artificial intelligence (AI) software that may facilitate earlier brain CT detection and triage of the potentially life-threatening condition of obstructive hydrocephalus (OHCP).
Based on assessment of non-contrast brain CT scans, the AI software provides passive and active notifications on suspected cases of OHCP, according to Annalise.ai, the developer of the software. The company noted that the OHCP software is the first triage device in radiology to receive the FDA’s Breakthrough Device Designation.
The FDA clearance of the OHCP software is the 10th FDA clearance for the company’s AI-powered software applications, including five software applications that can be utilized for head CT scans, according to Annalise.ai.
“Our advanced algorithms support radiologists by facilitating prioritization of non-contrast head CT studies with suspected critical findings, thereby optimizing radiology workflow,” noted Rick Abramson, the chief medical officer at Annalise.ai. “With its set of clearances, Annalise.ai promotes faster report turnaround times by identifying and elevating critical cases for immediate attention.”
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.